Publication | Closed Access

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Phase 1/2Neuro-oncologyDose-finding PortionBrain MetastasesMedicinePharmacologyPathologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung Cancer